The forgotten survivor: A comprehensive review on Non-Hodgkin lymphoma survivorship

Mohamad S. Alabdaljabar, Urshila Durani, Carrie A. Thompson, Louis S. Constine, Shahrukh K. Hashmi

Research output: Contribution to journalReview articlepeer-review


The number of non-Hodgkin lymphoma (NHL) survivors is increasing. With the advancement of NHL therapies, it is crucial to focus on the challenges these survivors may face. Three main categories are to be considered in NHL survivorship, including quality of life and uncertainty about the future, possible physical health complications (including cardiovascular disease, infertility, and subsequent neoplasms), and the impact of novel NHL treatments and their potential complications. The latter includes CAR T-cell therapy, monoclonal antibodies, checkpoint inhibitors, and hematopoietic stem cell transplantation. In this report, we aim to shed the light on these aspects and to discuss survivorship care plan for NHL.

Original languageEnglish (US)
Pages (from-to)1627-1637
Number of pages11
JournalAmerican journal of hematology
Issue number12
StatePublished - Dec 2022

ASJC Scopus subject areas

  • Hematology


Dive into the research topics of 'The forgotten survivor: A comprehensive review on Non-Hodgkin lymphoma survivorship'. Together they form a unique fingerprint.

Cite this